Systemic Corticosteroids Resolve Immune-related AEs in Ipilimumab-treated Metastatic Melanoma Patients

Share this content:

(CHICAGO, IL) – Systemic corticosteroids resolve immune-mediated adverse reactions associated with ipilimumab treatment, according to a study presented at the 2012 American Society of Clinical Oncology Annual Meeting.

Results from a previously published Phase 3 trial demonstrated that patients with previously untreated metastatic melanoma who received ipilimumab at 10mg/kg plus dacarbazine (DTIC) have improved overall survival. In these previously published ipilimumab studies, the most common drug-related adverse events (AEs) were immune-related, which were generally reversible using treatment guidelines involving prompt recognition, intervention (corticosteroids, and rarely, alternative immunosuppressive agents), and possible discontinuation of therapy, according to  lead study author Jean-Francois Baurain, MD, PhD, Medical Oncologist, Cliniques Universitaires Saint-Luc Cancer Centre, Brussels, Belgium.

Ipilimumab is a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4 to augment antitumor immune responses. In the current study, Baurain and colleagues aimed to evaluate outcomes of ipilimumab treatment-related AEs with use of systemic corticosteroids, reporting AEs from the first ipilimumab dose up to 70 days after the last dose. This analysis included AEs characterized as immune-mediated adverse reactions (imARs), which fell into the following categories: hepatitis, dermatitis, enterocolitis, and endocrinopathies.

The investigators reported that more than 70% of patients who received corticosteroids had complete resolution of the imAR, ie, the last reported AE had a grade of 0. By the time the final data were collected for analysis, high-grade imARs that had not been completely resolved improved to Grade 1 in ≥50% of patients.

Dr. Baurain and colleagues concluded that “in the majority of ipilimumab-DTIC-treated patients who received corticosteroids for the management of imARs, the most common imARs had completely resolved or improved to Grade 1.”


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs